Ovarian Cancer Cells Induce Peripheral Mature Dendritic Cells to Differentiate Into Macrophagelike Cells In Vitro

Chen, Fangxue; Hou, Meng; Ye, Feng; Lv, Wei-Guo; Xie, Xing

doi:10.1111/igc.0b013e3181bb70c6

Cited by 26 publications

(24 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Upon detection of danger through their pathogen-associated molecular pattern (PAMP) receptors or danger-associated molecular pattern (DAMP) receptors, DC mature and migrate to the lymph nodes to activate T helper cells and CTL [82]. Although tumors are able to produce danger signals, they are ineffective in inducing DC maturation and trafficking to lymph nodes which is thought to be due to tumor-induced alterations in DC differentiation, thus reducing the number of functional cells available for effective T cell activation [83]. For example, ovarian cancers secrete large amounts of IL-10 which promotes redifferentiation of mDCs to an aberrant phenotype with reduced T cell activation properties [83].…”

Section: Microenvironment: Role Of Tumor Infiltrating Immune Cells Inmentioning

confidence: 99%

“…Although tumors are able to produce danger signals, they are ineffective in inducing DC maturation and trafficking to lymph nodes which is thought to be due to tumor-induced alterations in DC differentiation, thus reducing the number of functional cells available for effective T cell activation [83]. For example, ovarian cancers secrete large amounts of IL-10 which promotes redifferentiation of mDCs to an aberrant phenotype with reduced T cell activation properties [83]. In murine modeling studies, our group has found that suppressor mDCs within ovarian cancers are induced to express high levels of PD-1 which reversibly suppresses expression of co-stimulatory molecules, reduces migration, and blocks responsiveness to danger signals [84].…”

Section: Microenvironment: Role Of Tumor Infiltrating Immune Cells Inmentioning

confidence: 99%

See 1 more Smart Citation

RETRACTED ARTICLE: Targeted immune therapy of ovarian cancer

Knutson

Karyampudi

Lamichhane

et al. 2014

Cancer Metastasis Rev

View full text Add to dashboard Cite

Clinical outcomes, such as recurrence free survival and overall survival, in ovarian cancer are quite variable, independent of common characteristics such as stage, response to therapy and grade. This disparity in outcomes warrants further exploration and therapeutic targeting into the interaction between the tumor and host. One compelling host characteristic that contributes both to the initiation and progression of ovarian cancer is the immune system. Hundreds of studies have confirmed a prominent role for the immune system in modifying the clinical course of the disease. Recent studies also show that anti-tumor immunity is often negated by immune regulatory cells present in the tumor microenvironment. Regulatory immune cells also directly enhance the pathogenesis through the release of various cytokines and chemokines, which together form an integrated pathologic network. Thus, in the future, research into immunotherapy targeting ovarian cancer will probably become increasingly focused on combination approaches that simultaneously augment immunity while preventing local immune suppression. In this article, we summarize important immunological targets that influence ovarian cancer outcome as well as include an update on newer immunotherapeutic strategies.

show abstract

Section: Microenvironment: Role Of Tumor Infiltrating Immune Cells Inmentioning

confidence: 99%

Section: Microenvironment: Role Of Tumor Infiltrating Immune Cells Inmentioning

confidence: 99%

RETRACTED ARTICLE: Targeted immune therapy of ovarian cancer

Knutson

Karyampudi

Lamichhane

et al. 2014

Cancer Metastasis Rev

View full text Add to dashboard Cite

show abstract

“…In addition, the cytokine profile in animals changed to one more supporting of anti-cancer immunity. These findings showed that not only proteins such as cytokines or tumor cells can be the target for new therapeutic strategies of ovarian cancer [39]. Our experiment also showed that unstimulated PBMCs have the ability to produce investigated cytokines, and after stimulation, the level of cytokines is changed.…”

Section: Discussionsupporting

confidence: 54%

“…Our experiment also showed that unstimulated PBMCs have the ability to produce investigated cytokines, and after stimulation, the level of cytokines is changed. Recently it was shown that not only cells or cytokines affect the anti-cancer immune response [39, 40]. Also immune cells and mesenchymal cells can interact with malignant cells.…”

Section: Discussionmentioning

confidence: 99%

Effect of Th1/Th2 cytokine administration on proinflammatory SKOV-3 cell activation

Mielczarek‐Palacz

Sikora

Kondera-Anasz

et al. 2016

aoms

View full text Add to dashboard Cite

IntroductionInterleukin(IL)-1β, IL-6 and IL-12 might associate with inflammatory processes in a tumor progression and create a specific microenvironment for tumor growth. The aim of the study was to assess whether the Th1 and Th2 type cytokines, such as IL-2 and IL-10, affect ovarian carcinoma continuous cell line (SKOV-3) pro-inflammatory activation.Material and methodsSKOV-3 ovarian cells and peripheral blood mononuclear cells (PBMCs) were stimulated by IL-2 and IL-10. Additionally, SKOV-3 ovarian cells and PBMCs were co-cultured together. Proinflammatory activation of cancer cells was evaluated by measurement of IL-1β and IL-6 levels in culture fluid after 72 h of incubation.ResultsSKOV-3 cells and PBMCs secreted IL-1β and IL-6. After stimulation by IL-2 and IL-10, secretion of studied parameters was changed in a dose-dependent manner. The addition of a higher IL-2 level gave rise to an increase of IL-1β, IL-6 and IL-12 secretion in SKOV-3 cells. Stimulation by IL-10 increased only IL-1β secretion in SKOV-3 cells. However, IL-6 secretion decreased after stimulation with 25 ng/ml IL-10. Activatory effects of IL-2 and inhibitory effects of IL-10 in co-culture of SKOV-3 and PBMCs were observed.ConclusionsOur results suggested that Th1/Th2 type of cytokines might influence pro-inflammatory activation of SKOV-3 ovarian cells. Co-cultures of SKOV-3 and PBMCs showed significant changes in cross-talk between cancer and immune cells.

show abstract

“…DCs, involved in T-cell activation, are not activated by tumors; human ovarian cancers contain either DC or their precursors, which could promote both angiogenesis and vasculogenesis during tumor growth [64][65][66][67]. In particular, the presence of DC expressing B7-H1 is associated with poor overall survival (OS) in ovarian cancer, probably by directly inhibiting T cell proliferation and by promoting the induction of FoxP3 + Tregs as well [68][69][70][71].…”

Section: Mechanisms Of Immunogenicity and Immunoediting In Ovarian Camentioning

confidence: 99%

Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?

Bronte

Cicero

Sortino

et al. 2013

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Introduction: Treatment of ovarian cancer has been long standardized with the inclusion of surgery and chemotherapy based on platinum and taxanes,\ud this strategy reaching high remission rates. However, when this treatment\ud fails, further options are available with little benefit. Since ovarian cancer\ud has specific immunologic features, actually immunotherapy is under evalua- 15\ud tion to overcome treatment failure in patients experiencing recurrence.\ud Areas covered: Immunogenicity of ovarian cancer and its relationship with\ud clinical outcomes is briefly reviewed. The kinds of immunotherapeutic strategies\ud are summarized. The clinical trials investigating immunotherapy in\ud recurrent ovarian cancer patients are reported. 20\ud Expert opinion: The results of these clinical trials about immunotherapy are\ud interesting, but little clinical benefit has been achieved until now. For this\ud reason, we could conclude that immunotherapy is quite different from other\ud treatment options and it could change the global approach for recurrent\ud ovarian cancer treatment. However, to date only fragmentary findings are 25\ud available to define the real role of immunotherapy in this setting

show abstract

Ovarian Cancer Cells Induce Peripheral Mature Dendritic Cells to Differentiate Into Macrophagelike Cells In Vitro

Cited by 26 publications

References 19 publications

RETRACTED ARTICLE: Targeted immune therapy of ovarian cancer

RETRACTED ARTICLE: Targeted immune therapy of ovarian cancer

Effect of Th1/Th2 cytokine administration on proinflammatory SKOV-3 cell activation

Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?

Contact Info

Product

Resources

About